Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms

Blood Advances 2026 Open access

Read full text
Authors: Orly Leiva, Steven Soo, Olivia C Liu, Victor You, Andrew Stephen Palmer, Justin Abraham Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Patrycja M. Dubielecka, Max Petersen
+3 more Michelle H Lee, Joan How, Gabriela Hobbs
DOI: 10.1182/bloodadvances.2025019152
Cited by: 2
References: 38

Abstract

ABSTRACT: Myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are a diverse group of hematopoietic stem cell neoplasms associated with an increased risk of hematologic progression to secondary MF or leukemia and cardiovascular disease (CVD). Elevated total cholesterol levels are traditional CVD risk factors. Patients with MPNs may have reduced cholesterol levels, potentially reflecting an underlying hypermetabolic state. The impact of serum total cholesterol on clinical outcomes in patients with MPNs has not yet been evaluated. We performed a multicenter retrospective cohort study of patients with MPNs who had transthoracic echocardiogram (TTE) with available serum lipid levels at time of TTE not on statin therapy. Patients were categorized by total cholesterol level (≥150, 120-149, and

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Eosinophilic Disorders and Syndromes

Publication details

Journal / source
Blood Advances
Publisher
American Society of Hematology
Volume
10
Issue
10
Pages
3746–3755
Publication date
4 March 2026
Language
EN